ILYANG PHARMACEUTICALII

ILYANG PHARMACEUTICAL

12,290KRWD
−430−3.38%
At close at Jan 10, 08:40 UTC
KRW
No trades
See on Supercharts

007570 fundamentals

Key facts

Market capitalization‪231.57 B‬KRW
Basic EPS (TTM)−45.45KRW
Founded1946
CEO
About

Ilyang Pharmaceutical Co., Ltd. engages in the manufacture, development, and distribution of pharmaceutical drugs. The firm's products include medicine, food, cosmetic, and antacid raw materials. It operates through the following business divisions: Ilyang Pharmaceutical, Yangju Ilyang, Ilyang Biopharm, and Cantech. The Ilyang Pharmaceutical business division offers prescription drugs, over-the-counter (OTC) medicine, health supplements, and export of raw drug products. The Yangju Ilyang business division refers to antacids prescription drugs. The Ilyang Biopharma business division pertains to anti-inflammatory drugs. The Cantech business division consists of the BizXR ERP trademark. The company was founded on July 1, 1946 and is headquartered in Yongin-si, South Korea.

Ownership
‪‪17.97 M‬‬
Free Float shares
‪‪11.40 M‬‬ (63.41%)
Closely held shares
‪‪6.58 M‬‬ (36.59%)
Free Float shares
‪‪11.40 M‬‬ (63.41%)
Closely held shares
‪‪6.58 M‬‬ (36.59%)
Capital structure
Market cap
‪‪231.57 B‬‬
Debt
‪‪122.55 B‬‬
Minority interest
‪‪39.05 B‬‬
Preferred stock
‪‪1.11 B‬‬
Cash & equivalents
‪‪25.89 B‬‬
Enterprise value
‪‪368.39 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪231.57 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
0.63x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
0.63x
Valuation ratios
‪0.00‬
‪0.20‬
‪0.40‬
‪0.60‬
‪0.80‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪110.00‬
‪220.00‬
‪330.00‬
‪440.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−8%‬
‪−4%‬
‪0%‬
‪4%‬
‪8%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−40.00 B‬‬
‪0.00‬
‪‪40.00 B‬‬
‪‪80.00 B‬‬
‪‪120.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪25.00 B‬‬
‪‪50.00 B‬‬
‪‪75.00 B‬‬
‪‪100.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪25.00 B‬‬
‪‪50.00 B‬‬
‪‪75.00 B‬‬
‪‪100.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Pharmaceutical
By country
Period: 2023
South Korea
Overseas

Dividends

Dividend yield, history and sustainability

Dividend summary
−330.06%
Payout ratio (TTM)
Dividend yield TTM
1.18%
Last payment
150.00
Last ex-date
Dec 27, 2024
Dividend history
‪0.15%‬
‪0.36%‬
‪0.57%‬
‪0.78%‬
‪0.99%‬
2019
2020
2021
2022
2023
‪0.00‬
‪50.00‬
‪100.00‬
‪150.00‬
‪200.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−45.00 B‬‬
‪0.00‬
‪‪45.00 B‬‬
‪‪90.00 B‬‬
‪‪135.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪90.00 B‬‬
‪‪180.00 B‬‬
‪‪270.00 B‬‬
‪‪360.00 B‬‬
Assets
Liabilities